The EUFEMED conference spotlights exploratory development of novel therapeutic approaches – lessons learned in the pandemic. Join regulators, sponsors and CROs to hear how the industry has overcome the challenge of conducting clinical research during a global pandemic.
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
Discover the intricacies of assessing abnormal liver functions in clinical trial volunteers and gain insights from the latest drug development trials using RNAi therapeutics.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.